Health Library

 

Hepatitis B Treatment Recommendations

Topic Overview

The American Association for the Study of Liver Disease has made recommendations for treating long-term (chronic) hepatitis B. These recommendations are based on the presence of hepatitis B antigens in your blood, the level of hepatitis B viral DNA (HBV DNA) in your blood, and the level of the liver enzyme alanine aminotransferase (ALT).

Chronic hepatitis B can be HBeAg-positive or -negative. This means a specific hepatitis B antigen (HBeAg) is present (positive) or is not present (negative) in your blood. High levels of HBV DNA and liver enzymes may be present in both of these types of chronic hepatitis. This points to an active viral infection and increased risk of liver damage.

Treatment with antiviral medicine is recommended if you are:1

  • HBeAg-positive and have high levels of HBV DNA, and your ALT level is more than twice the normal level.
  • HBeAg-negative and have lower levels of HBV DNA, and your ALT level is more than twice the normal level.
  • Either HBeAg-positive or negative, have high levels of HBV DNA, and have cirrhosis.

Treatment with antiviral medicine is not recommended if you are:1

  • HBeAg-positive and have high levels of HBV DNA, and your liver enzymes are less than twice the normal level.
  • HBeAg-negative and have low levels of HBV DNA, and your liver enzymes are less than twice the normal level.

If you are either HBeAg-positive or -negative, have low levels of HBV DNA, and have cirrhosis, you may be monitored or may need a liver transplant.

The European Association for the Study of the Liver (EASL) also has guidelines for the treatment of chronic hepatitis B. According to the EASL, treatment should be considered for people with high levels of HBV DNA and/or higher-than-normal levels of the liver enzyme ALT, and moderate to severe liver inflammation. But the decision to treat should also consider a person's general health, age, and availability of antiviral medicines.2

References

Citations

  1. Lok SFL, McMahon BJ (2009). Chronic Hepatitis B: Update 2009. Available online: http://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/Chronic_Hep_B_Update_2009%208_24_2009.pdf.
  2. European Association for the Study of the Liver (2012). EASL Clinical Practice Guidelines: Management of chronic hepatitis B. Journal of Hepatology, 57(1): 167–185.

Credits

By Healthwise Staff
Primary Medical Reviewer Kathleen Romito, MD - Family Medicine
Specialist Medical Reviewer W. Thomas London, MD - Hepatology
Last Revised October 29, 2012

Last Revised: October 29, 2012

This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.

© 1995-2013 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.

First Nurse

First Nurse

Call First Nurse 24 Hours a Day for free health care advice, resources and referrals!

Ames: 515-239-6877
In Iowa: 800-524-6877 

Search health information online in our Mulimedia Health Library.

High Quality Care

Guardian of Excellence

Mary Greeley consistently delivers high quality patient care.

  • 2013 Guardian of Excellence Award for Clinical Quality
  • Grade 'A' Patient Safety from the Leapfrog Group
  • 2013 Top Performer on Key Quality Measures ranking from The Joint Commission
  • Highest percentage bonus of any Iowa hospital in Medicare's quality incentive program

Mary Greeley on Facebook

Like us on Facebook

Patient Privacy | Net Learning for Employees | MGMC PACS for Physicians
Emergency Preparedness

1111 Duff Avenue Ames, IA 50010 - 515-239-2011 - yourhealth.mgmc@mgmc.com

©2014 Mary Greeley Medical Center - All rights reserved.